Albany, NY -- (SBWIRE) -- 03/01/2018 -- Bovine respiratory disease (BRD) is a multifactorial and complex disorder caused due to combination of more than one microbial pathogens, impaired host immunity, inadequate housing conditions, and environmental factors. The major factor leading to bovine respiratory diseases are host factors, environmental factors, and direct influence of infectious agents such as virus, bacteria, and parasites. However, due to increasing consumption of milk and beef products, the need for bovine respiratory disease treatment has increased across the globe.
Report Overview @ https://www.transparencymarketresearch.com/bovine-respiratory-disease-treatment-market.html
Moreover, according to the World Bank Group (2016), global human population is estimated to be 7.4 billion in 2016 and is growing at a rate of 1.8% per year. Hence, demand for beef has increased due to rising population and increasing disposable income across the world. The rising demand for high quality bovine derived products is influencing the bovine respiratory disease treatment market. Despite of innovations in veterinary medicines and advancement in technology, bovine respiratory disease is the leading cause to impact negatively on both the dairy and beef industries due to calf mortality, additional labor cost and treatment expenses. Moreover, bovine respiratory disease affects adversely on reproductive performance, growth and longevity of cattle. Hence, prevention and treatment of bovine respiratory disease have become important to decrease the impact on animal production and the beef industry. Therefore, the bovine respiratory disease treatment market is anticipated to witness significant growth in terms of revenue during the forecast period.
In terms of treatment type, the bovine respiratory disease treatment market has been categorized into vaccines, antibiotics, NSAIDs, and immunomodulators. Causative agents such as viruses leading to bovine respiratory disease have no direct treatment. Hence, vaccination is the preferred choice of preventive action against the disease. This increase market potential for vaccines. However, virus infected cattle is exposed to bacteria, parasites, and various other factors. Therefore, antibiotics are the preferred choice of treatment for bovine respiratory diseases. Effective treatment and significant demand has increased the scope for antibiotics in the bovine respiratory disease treatment market.
However, according to NCBI report, combination treatment with anti-inflammatory drugs such as NSAIDs has better results over the monotherapy of antibiotics. This has led to increase in usage of NSAIDs in bovine respiratory disease treatment. Bovine respiratory disease is generally treated with several combination therapies. However, growing resistance to antibiotics and drying pipeline has increased demand for novel treatment options for which cattle do not develop resistance, and consequently there is no impact on human life.
Request for Sample Copy of Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=13700
Development of newer generation antibiotics for cattle is anticipated to drive the global bovine respiratory disease treatment market during the forecast period. In order to avoid the issue of antibiotics resistance in bovine population, preventive measures such as vaccination and immunomodulators has observed increased global acceptance against the bovine respiratory disease. Hence, preventive treatment is gaining momentum due to growing awareness about the negative impact of antibiotics on human health. This has driven the market for immunomodulators, vitamin injections, and other immunity building products.
In terms of disease type, the market has been segmented into upper respiratory tract infections, diphtheria, and pneumonia (lower respiratory tract infection). Upper respiratory tract infections dominated the global bovine respiratory disease market, accounting for significant share in terms of revenue in 2015. Respiratory infections first affect the upper respiratory tract, which is also the most vulnerable region, followed by other parts of the respiratory tract. Diphtheria accounted for significant share of the bovine respiratory disease treatment market in 2015. Pneumonia (lower respiratory tract infection) accounted for high market share, followed after upper respiratory tract infection in 2015. Hence, early detection of infection is important in bovine respiratory diseases treatment.
In terms of distribution channel, the global bovine respiratory disease treatment market has been segmented into veterinary hospitals, veterinary clinics, private veterinary pharmacies, and veterinary research institutes. Veterinary hospitals dominated the global bovine respiratory disease market in 2015. The segment dominated the market due to factors such as rising population of cattle which increases prevalence of bovine respiratory diseases. The private veterinary pharmacies distribution channel segment is projected to register significant CAGR during the forecast period. The segment is likely to witness strong growth in most of the emerging parts of the world and preference for medicines from private veterinary pharmacies for bovine serum respiratory diseases. However, the veterinary clinics and veterinary research institutes segments are expected to grow steadily as majority of procedures are carried out in veterinary hospitals.
Request a Brochure of the Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=13700
Geographically, the bovine respiratory disease treatment market has been categorized in five major regions: North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. North America held the major share of the global bovine respiratory disease treatment market in 2015, where the U.S. dominates the market in terms of revenue. Europe accounted for a significant share of the market in 2015. Changing environmental factors, growing prevalence of causative agents for respiratory disease, increasing demand for quality bovine products, and rising bovine population are the key factors driving the bovine respiratory disease treatment market in Europe. Asia Pacific is the largest producer of bovine livestock. Hence, it presents significant opportunities in the bovine respiratory disease treatment market. India and China are the key markets for bovine respiratory disease treatment, as these have largest livestock population compared to other countries across the globe. Latin America and Middle East & Africa have comparatively smaller markets for bovine respiratory disease treatment. However, Brazil, Mexico, and Argentina are the emerging markets in Latin America due to significant number of livestock population.
Key players operating in the global bovine respiratory disease treatment market are Merck & Co., Inc., Zoetis Services LLC, Bayer AG, Elanco, Merial, Boehringer Ingelheim GmbH, Virbac Group, Ceva, Vetoquinol, and Bimeda Animal Health, among others.
Enquiry for discount on this report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=13700
About Transparency Market Research
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR's experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR's syndicated reports strive to provide clients to serve their overall research requirement.